OPTIMUS-EL: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy (clinicaltrials.gov) - Dec 4, 2025 - P2 | N=40 | Recruiting | Sponsor: Seoul National University Hospital | Not yet recruiting ➔ Recruiting
Enrollment open • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology
|